MED Stock Overview
Through its subsidiaries, engages in the manufacture and sale of weight loss, weight management, and healthy living products in the United States and the Asia-Pacific. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Community Narratives
Create a narrativeNarratives bring a range of perspectives from our community.
Medifast, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$16.92 |
| 52 Week High | US$70.58 |
| 52 Week Low | US$16.73 |
| Beta | 1.17 |
| 1 Month Change | -8.09% |
| 3 Month Change | -10.00% |
| 1 Year Change | -74.62% |
| 3 Year Change | -91.71% |
| 5 Year Change | -84.38% |
| Change since IPO | 207.64% |
Recent News & Updates
Medifast, Inc.'s (NYSE:MED) Business And Shares Still Trailing The Industry
Dec 11
Medifast: Earnings Surprise, New AI Technologies, And Extremely Undervalued
Nov 06Recent updates
Medifast, Inc.'s (NYSE:MED) Business And Shares Still Trailing The Industry
Dec 11Medifast: Earnings Surprise, New AI Technologies, And Extremely Undervalued
Nov 06Medifast: Reorganization, GLP-1 Medication, And FCF Imply Undervaluation
Sep 03Medifast Business Continues To Shrink, Stock Still Risky
Aug 27Medifast: GLP-1 Fears Are Overblown, But Proof Points For Turnaround Are Still Missing
Jun 26Medifast: Significant Undervaluation Even As Struggles Persist
May 24At US$22.76, Is Medifast, Inc. (NYSE:MED) Worth Looking At Closely?
May 24Lacklustre Performance Is Driving Medifast, Inc.'s (NYSE:MED) 32% Price Drop
May 24Medifast's (NYSE:MED) Conservative Accounting Might Explain Soft Earnings
May 06The Returns On Capital At Medifast (NYSE:MED) Don't Inspire Confidence
May 01Medifast: Cheap Valuation, Uncertain Future
Mar 20Medifast Is Getting Attractive
Mar 07Medifast, Inc.'s (NYSE:MED) 26% Dip In Price Shows Sentiment Is Matching Earnings
Feb 22Medifast Share Price Loses Weight, But Is There Still Value To Be Had?
Jan 20Are Investors Undervaluing Medifast, Inc. (NYSE:MED) By 47%?
Dec 09Medifast: Good On Paper, But A Slowdown In Sales Is Very Worrisome
Nov 24Is It Too Late To Consider Buying Medifast, Inc. (NYSE:MED)?
Nov 21Medifast: Unveiling A Challenge Beyond Weight Loss Drugs
Nov 09Medifast: The Race To Weight-Loss Drugs Not Lost Yet
Oct 09Medifast: Take Advantage Of Pessimism Over Weight Loss Drugs
Aug 04Is Now An Opportune Moment To Examine Medifast, Inc. (NYSE:MED)?
Jul 26In The Murky MLM Space, Medifast Might Actually Hold Some Promise
Jul 21Estimating The Intrinsic Value Of Medifast, Inc. (NYSE:MED)
Jul 05Medifast: In Survival Mode Against Diet Pills And The Recession
Jun 14Medifast Holds Value During Headwinds
May 28Medifast Non-GAAP EPS of $3.70 beats by $1.48, revenue of $337.2M beats by $7.1M
Feb 21Medifast: A Low Earnings Multiple Despite Strong Financial Performance
Feb 07At US$117, Is Medifast, Inc. (NYSE:MED) Worth Looking At Closely?
Jan 19Medifast declares $1.64 dividend
Dec 08A Look At The Intrinsic Value Of Medifast, Inc. (NYSE:MED)
Dec 01Medifast's (NYSE:MED) Sluggish Earnings Might Be Just The Beginning Of Its Problems
Nov 10One Medifast, Inc. (NYSE:MED) Analyst Just Made A Major Cut To Next Year's Estimates
Nov 08Medifast: This High-Yield Blue Chip Dividend Stock Is A Strong Buy
Nov 06What Does Medifast, Inc.'s (NYSE:MED) Share Price Indicate?
Oct 20We Think Medifast (NYSE:MED) Can Stay On Top Of Its Debt
Sep 18Medifast declares $1.64 dividend
Sep 08Do Medifast's (NYSE:MED) Earnings Warrant Your Attention?
Sep 02Shareholder Returns
| MED | US Personal Products | US Market | |
|---|---|---|---|
| 7D | -11.7% | -5.0% | -2.4% |
| 1Y | -74.6% | -24.7% | 23.4% |
Return vs Industry: MED underperformed the US Personal Products industry which returned -24.7% over the past year.
Return vs Market: MED underperformed the US Market which returned 23.4% over the past year.
Price Volatility
| MED volatility | |
|---|---|
| MED Average Weekly Movement | 6.5% |
| Personal Products Industry Average Movement | 8.2% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: MED has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: MED's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1980 | 634 | Dan Chard | medifastinc.com |
Medifast, Inc., through its subsidiaries, engages in the manufacture and sale of weight loss, weight management, and healthy living products in the United States and the Asia-Pacific. It offers bars, puffs, cereal, crunchers, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups under the OPTAVIA, OPTAVIA ACTIVE, and Optimal Health brand names. The company markets its products through point-of-sale transactions, as well as through ecommerce platform.
Medifast, Inc. Fundamentals Summary
| MED fundamental statistics | |
|---|---|
| Market cap | US$180.23m |
| Earnings (TTM) | US$7.33m |
| Revenue (TTM) | US$674.48m |
24.6x
P/E Ratio0.3x
P/S RatioIs MED overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MED income statement (TTM) | |
|---|---|
| Revenue | US$674.48m |
| Cost of Revenue | US$176.70m |
| Gross Profit | US$497.77m |
| Other Expenses | US$490.45m |
| Earnings | US$7.33m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.69 |
| Gross Margin | 73.80% |
| Net Profit Margin | 1.09% |
| Debt/Equity Ratio | 0% |
How did MED perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 03:23 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Medifast, Inc. is covered by 12 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Anand Vankawala | Avondale Partners |
| Kara Anderson | B. Riley Securities, Inc. |
| Scott Van Winkle | Canaccord Genuity |